Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
- Barclays Capital Report Mentions Tivozanib, Raises Astellas Pharma’s Target Stock Price
January 12, 2012
- Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
January 12, 2012
- Sales of Ethical Drugs Up 5.2% in November: Crecon Report
January 12, 2012
- Administration of OTSA101 Started in Trial for Synovial Sarcoma: OncoTherapy
January 12, 2012
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
- Current Pollinosis Treatments Least Effective at Relieving Nasal Congestion: MSD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
- DSP to Change Brand Name of Almarl to Avoid Confusion
January 11, 2012
- Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Interprotein, Takeda to Collaborate on Molecular Designing of PPI Modulators
January 11, 2012
- Observation Period Ended in PII/III Trial of Elpamotide: OncoTherapy
January 11, 2012
- DWTI’s Antiplatelet Agent Enters Late PII Stage
January 11, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…